Flythe JE, Forfang D, Gedney N, White DM, Wilkie C, Cavanaugh K, Harris RC, Unruh M, Squillaci G, West M, Mansfield C, Soloe CS, Treiman K, Wood D, Hurst FP, Neuland C, Saha A, Sheldon M, Tarver ME. Development of a patient preference survey for wearable kidney replacement therapy devices. Kidney360. 2022 May 5;3(7):1197-209. doi: 10.34067/KID.0001862022
Manga N, Duffy JC, Rowe PH, Cronin MTD. Structure-based methods for the prediction of the dominant P450 enzyme in human drug biotransformation: consideration of CYP3A4, CYP2C9, CYP2D6. SAR QSAR Environ Res. 2005 Feb;16(1-2):43-61.
Walker EA, Picker MJ, Granger AL, Dykstra LA. Effects of opioids in morphine-treated pigeons trained to discriminate among morphine, the low-efficacy agonist nalbuphine, and saline. J Pharmacol Exp Ther. 2004 Jul;310(1):150-8.
Allen RM, Granger AL, Dykstra LA. The competitive N-methyl-D-aspartate receptor antagonist (-)-6-phosphonomethyl-deca-hydroisoquinoline-3-carboxylic acid (LY235959) potentiates the antinociceptive effects of opioids that vary in efficacy at the mu-opioid receptor. J Pharmacol Exp Ther. 2003 Nov 1;307(2):785-92.
Cronin MT, Dearden JC, Duffy JC, Edwards R, Manga N, Worth AP, Worgan AD. The importance of hydrophobicity and electrophilicity descriptors in mechanistically-based QSARs for toxicological endpoints. SAR QSAR Environ Res. 2002 Mar;13(1):167-76.
Allen RM, Granger AL, Dykstra LA. Dextromethorphan potentiates the antinociceptive effects of morphine and the delta-opioid agonist SNC80 in squirrel monkeys. J Pharmacol Exp Ther. 2002 Feb 1;300(2):435-41.